My MMJ Doctor's new Dispensary Partner Program offers cannabis retailers affiliate commissions on medical card evaluations, providing a new revenue st...
Helus Pharma's HLP003 and HLP004 could transform treatment for major depressive disorder and generalized anxiety disorder, pending late-stage trial re...
Oklahoma's HB 3127, effective November 1, 2026, allows employers to take adverse action based on positive marijuana tests under compliant written poli...
Sage Dispensary has opened at the former Sage Diner in Mount Laurel, New Jersey, led by South Jersey native Alex Kardos, blending cannabis retail with...
Mule Extracts is urging Estacada voters to consider the economic impact of Measure 3-638, which would ban new marijuana production, processing, and wh...
The Citizens Commission on Human Rights International has formally opposed FDA approval of psychedelic drugs for mental health treatment, warning of s...
NeuroThera Labs has expanded its U.S. patent portfolio through a collaboration with Clearmind Medicine, covering novel combinations of LSD, ketamine, ...
Helus Pharma presented four posters on its investigational oral deuterated psilocin analog HLP003 at Psych Congress 2026, including 12-month efficacy ...
Optimi Health Corp. plans a Health Canada-authorized Phase 3 clinical trial of MDMA-assisted therapy for PTSD, targeting veterans and frontline worker...
Buddy's ecommerce platform now powers over 300 live storefronts and integrates POSaBIT Pay for online and in-store payments, offering dispensaries a f...
Optimi Health Corp. plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder in the f...
Helus Pharma's CEO participation at the Cantor conference underscores the company's advancing clinical trials for depression and anxiety treatments, s...
